Paul L Crispen
Overview
Explore the profile of Paul L Crispen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
83
Citations
2026
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Mi X, Zou B, Rashidi P, Baharloo R, Fillingim R, Wallace M, et al.
Clin J Pain
. 2021 Sep;
37(11):803-811.
PMID: 34475340
Objective: Acute postoperative pain intensity is associated with persistent postsurgical pain (PPP) risk. However, it remains unclear whether acute postoperative pain intensity mediates the relationship between clinical factors and persistent...
12.
Grajo J, Batra N, Bozorgmehri S, Magnelli L, OMalley P, Terry R, et al.
Abdom Radiol (NY)
. 2021 Aug;
46(12):5629-5638.
PMID: 34463815
Introduction And Background: Several features noted on renal mass biopsy (RMB) can influence treatment selection including tumor histology and nuclear grade. However, there is poor concordance between renal cell carcinoma...
13.
Grajo J, Batra N, Bozorgmehri S, Magnelli L, Pavlinec J, OMalley P, et al.
Abdom Radiol (NY)
. 2021 Mar;
46(7):3269-3279.
PMID: 33665734
Objectives: We previously noted that the aorta-lesion-attenuation difference (ALAD) determined on CT scan discriminated well between chromophobe RCC and oncocytoma. The current evaluation seeks to validate these initial findings in...
14.
Baharloo R, Principe J, Fillingim R, Wallace M, Zou B, Crispen P, et al.
Anesth Analg
. 2021 Feb;
132(5):1465-1474.
PMID: 33591118
Background: Evidence suggests that increased early postoperative pain (POP) intensities are associated with increased pain in the weeks following surgery. However, it remains unclear which temporal aspects of this early...
15.
Vasilopoulos T, Wardhan R, Rashidi P, Fillingim R, Wallace M, Crispen P, et al.
Anesthesiology
. 2021 Jan;
134(3):421-434.
PMID: 33449996
Background: The primary goal of this study was to evaluate patterns in acute postoperative pain in a mixed surgical patient cohort with the hypothesis that there would be heterogeneity in...
16.
Boorjian S, Alemozaffar M, Konety B, Shore N, Gomella L, Kamat A, et al.
Lancet Oncol
. 2020 Nov;
22(1):107-117.
PMID: 33253641
Background: BCG is the most effective therapy for high-risk non-muscle-invasive bladder cancer. Nadofaragene firadenovec (also known as rAd-IFNa/Syn3) is a replication-deficient recombinant adenovirus that delivers human interferon alfa-2b cDNA into...
17.
Dominguez-Gutierrez P, Kwenda E, Donelan W, OMalley P, Crispen P, Kusmartsev S
Cancer Res
. 2020 Nov;
81(3):648-657.
PMID: 33239427
The increased presence of myeloid-derived suppressor cells (MDSC) and tumor-associated macrophages (TAM) in tumor tissue has been extensively reported. However, their role in the regulation of hyaluronan (HA) metabolism in...
18.
Crispen P, Kusmartsev S
Cancer Immunol Immunother
. 2019 Dec;
69(1):3-14.
PMID: 31811337
With the introduction of multiple new agents, the role of immunotherapy is rapidly expanding across all malignancies. Bladder cancer is known to be immunogenic and is responsive to immunotherapy including...
19.
Grajo J, Terry R, Ruoss J, Noennig B, Pavlinec J, Bozorgmehri S, et al.
Urology
. 2018 Dec;
125:123-130.
PMID: 30552939
Objective: To evaluate the ability of Aorta-Lesion-Attenuation Difference (ALAD) to differentiate malignant renal tumors from renal oncocytomas. Methods: A retrospective review of preoperative computed tomography (CT) scans and surgical pathology...
20.
Noennig B, Bozorgmehri S, Terry R, Otto B, Su L, Crispen P
Bladder Cancer
. 2018 Nov;
4(4):389-394.
PMID: 30417049
Background: Results of randomized trials support a single dose of intravesical chemotherapy following radical nephroureterectomy (RNU) for urothelial carcinoma. Objective: To evaluate the impact of the timing of intravesical mitomycin...